Medical Advocates
Efavirenz (Sustiva/Strocrin)
 
Journal Citations: Treatment Strategies
 
Dosage  
 Simplification Therapy
Intensification Therapy
Treatment Interruption
Switching Therapies
Salvage Therapy
Hepatic Disease
 Renal Disease
Metabolic Disorders
Neurological  Disorders		 HIV/HCV Coinfection
HIV/TB Coinfection
HIV/Malaria Coinfection
HBV Infection
TB Infection
Oncology

 
 
Efavirenz Adult Treatment Main New/Newsworthy  Home Page      
Last Update:  April 24, 2018
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 
 
FULL-TEXT ARTICLE
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial.
Turkova A, Moore CL, Butler K et al 
PLoS One. 2018 Apr 23;13(4):e0196239
 Paper

Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines.
Patel RC, Morroni C, Scarsi KK, et al
 J Int AIDS Soc. 2017 May 11;20(1):1
 Abstract

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial.
 BREATHER (PENTA 16) Trial Group
.Lancet HIV. 2016 Sep;3(9):e421-30.
Abstract
Dosage
 
 
Efavirenz dose reduction in HIV-infected patients.
Lanzafame M, Bonora S, Lattuada E, Vento S.
HIV Med. 2012 Apr;13(4):252-3. d
 Abstract

Efficacy and Safety of Once-Daily Nevirapine- or Efavirenz-Based Antiretroviral Therapy in HIV-Associated Tuberculosis: A Randomized Clinical Trial.
 Swaminathan S, Padmapriyadarsini C, Venkatesan P,  et al
Clin Infect Dis. 2011 Oct;53(7):716-24.
 Abstract

The Impact of Once-Nightly Versus Twice-Daily Dosing and Baseline Beliefs About HAART on Adherence to Efavirenz-Based HAART Over 48 Weeks: The NOCTE Study.
 Cooper V, Horne R, Gellaitry G, et al
J Acquir Immune Defic Syndr. 2010 Mar 1;53(3):369-77.
 Abstract

The Impact of Once-Nightly Versus Twice-Daily Dosing and Baseline Beliefs About HAARTon Adherence to Efavirenz-Based HAART Over 48 Weeks: The NOCTE Study.
 Cooper V, Horne R, Gellaitry G, et al 
J Acquir Immune Defic Syndr. 2010 Jan 19
 Abstract

Efavirenz Dose Reduction Is Safe in Patients With High Plasma Concentrations and May Prevent Efavirenz Discontinuations.
van Luin M, Gras L, Richter C, et al
J Acquir Immune Defic Syndr. 2009 Jul 10.
 Abstract

tepped-Dose vs. Full-Dose Efavirenz for HIV Infection and Neuropsychiatric Adverse Events: A Randomized Trial.
Gutiérrez-Valencia A, López-Cortés LF, et al
 Ann Intern Med. 2009 Jul 6
 Abstract

Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
 Gatanaga H, Hayashida T, Tsuchiya K, et al  
 Clin Infect Dis. 2007 Nov 1;45(9):1230-7.
Abstract


Outcomes of dosage adjustments used to manage antiretroviral drug interactions.
 Park-Wyllie LY, Levine MA, Holbrook A, et al
Clin Infect Dis. 2007 Oct 1;45(7):933-
Abstract  
Simplification Therapy
 
  Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.
 de Echaguen AO, Arnedo M, Xercavins M, et al
AIDS. 2005 Sep 2;19(13):1385-1391.
Abstract
Intensification Therapy
 
  Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
Gulick RM, Lalama CM, Ribaudo HJ, et al
AIDS. 2007 Apr 23;21(7):813-823.
Abstract
Treatment Interruption
 
 
Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
 Darwich L, Esteve A, Ruiz L, et al
Antivir Ther. 2008;13(7):945-51.
 Abstract
Switching Therapy
 
 
BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
Butler K, Inshaw J, Ford D,  et al
Health Technol Assess. 2016 Jun;20(49):1-108.
 Abstract

Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
 Bommenel T, Launay O, Meynard JL, et al
J Antimicrob Chemother. 2011 Jun 1
 Abstract

Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological
failure in virologically suppressed patients.
Campo RE, Cohen C, Grimm K, et al
Int J STD AIDS. 2010 Mar;21(3):166-71.
 Abstract

Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.
 Kiertiburanakul S, Malathum K, Watcharananan S, et al
 Int J STD AIDS. 2009 Mar;20(3):176-9.
 Abstract

Switch to Efavirenz (EFV) after Protease-inhibitor (PI) - Failure: Explorative Analysis of Outcome by Baseline Viral VS Tolerability Failure.
 Khaykin P, Postel N, Reeb I, Staszewski S
 Eur J Med Res. 2008 Apr 30;13(4):169-72.
 Abstract

Is it safe to switch between efavirenz and nevirapine in the event of toxicity?
 Mehta U, Maartens G.
 Lancet Infect Dis. 2007 Nov;7(11):733-8.
 Abstract
 

Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
 Abgrall S, Yeni PG, Bouchaud O, et al
 Clin Infect Dis. 2007 Jan 1;44(1):120-7.
 Abstract
 
Switch from a first virologically effective protease inhibitor-containing regimen to a
regimen containing efavirenz, nevirapine or abacavir.
 Abgrall S, Yeni PG, Bouchaud O, et al 
AIDS. 2006 Oct 24;20(16):2099-106.
 Abstract
 
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.
Fisac C, Fumero E, Crespo M, et al
AIDS. 2005 Jun 10;19(9):917-925
 Abstract

Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.
 Saah AJ, Haas DW, DiNubile MJ, et al.
 J Infect Dis 2003 Apr 1;187(7):1157-62
 Abstract
  Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups :a case-control study from the Swiss HIV Cohort,
Hirschel B, Flepp M, Bucher HC, et al .
 AIDS 2002 Feb 15;16(3):381-385
 Abstract
  Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to  efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression.
Negredo E, Cruz L, Paredes R, Ruiz L, et al.
 Clin Infect Dis 2002 Feb 15;34(4):504-10
Abstract
  Switch to efavirenz in a protease inhibitor-containing regimen.
Knechten H, Sturner KH, Hohn C, Braun P.
HIV Clin Trials 2001 May-Jun;2(3):200-4
 Abstract
Salvage Therapy
 
 
Genotypic resistance profile in treatment-experienced HIV-infected individuals after abacavir and efavirenz salvage regimen.
 Vallejo A, Olivera M, Rubio A, et al.
Antiviral Res. 2004 Feb;61(2):129-32
 Abstract

Modulation of Human Immunodeficiency Virus (HIV)-Specific Immune Response by Using Efavirenz, Nelfinavir, and Stavudine in a Rescue Therapy Regimen for HIV-Infected, Drug-Experienced Patients.
Trabattoni D, Lo Caputo S, Biasin M, et al.
Clin Diagn Lab Immunol 2002 Sep;9(5):1114-8
 Abstract

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.
 Antinori A, Zaccarelli M, Cingolani A, et al.
AIDS Res Hum Retroviruses 2002 Aug 10;18(12):835-8
 Abstract

  
Hepatic Disease
 
  Efavirenz-therapy in HIV-patients with Underlying Liver Disease: Importance of Continuous TDM of EFV.
Katsounas A, Frank A, Klinker H, Langmann P.
 Eur J Med Res. 2007 Aug 16;12(8):331-6
 Abstract
Renal Disease
 
  Experience with efavirenz in end-stage renal disease.
Prime KP, Woolfson RG, Pakianathan MR
 Int J STD AIDS. 2003 Jul;14(7):497-8.
 Abstract
Metabolic Disorders
 
 
Impact of Efavirenz on Intestinal Metabolism and Transport: Insights From an Interaction Study With Ezetimibe in Healthy Volunteers.
Oswald S, Meyer Zu Schwabedissen HE, et al
Clin Pharmacol Ther. 2012 Feb 1.
 Abstract

The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy.
 Pérez-Molina JA, Domingo P, Martínez E, Moreno S.
J Antimicrob Chemother. 2008 May 14
 Abstract

Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients.
 Pereira SA, Branco T, Corte-Real RM,
 Br J Clin Pharmacol. 2006 May;61(5):601-4
 Abstract

Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia.
 Calza L, Manfredi R, Colangeli V, et al 
AIDS. 2005 Jul 1;19(10):1051-8. R
 Abstract
 
Neurological Disorders
 
  Does efavirenz replacement improve neurological function in treated HIV infection?
 Payne B, Chadwick TJ, Blamire A,et al
HIV Med. 2017 Mar 1.
Abstract

Effect of Concomitant Use of Montelukast and Efavirenz on Neuropsychiatric Adverse Events.
 Ibarra-Barrueta O, Palacios-Zabalza I, et al
Ann Pharmacother. 2013 Nov 5.
 Abstract
HIV/HCV Coinfection
 
 
Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis.
 Pineda JA, Neukam K, Mallolas J,  et al
J Infect. 2011 Nov 25.
Abstract

Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C.
 Meynard JL, Lacombe K, Poirier JM, et al 
J Antimicrob Chemother. 2009 Jan 23.
 Abstract

Effect of Treatment With Efavirenz on Neuropsychiatric Adverse Events of Interferon in HIV/HCV-Coinfected Patients.
 Quereda C, Corral I, Moreno A, Pérez-Elías MJ,
 J Acquir Immune Defic Syndr. 2008 Jul 23.
Abstract
HIV/Tuberculosis Coinfection
 
 
Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.
 Habtewold A, Makonnen E, Amogne W, et al
Pharmacogenomics. 2015 Apr 1:1-17.
Abstract

FULL-TEXT ARTICLE
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial.
Turkova A, Moore CL, Butler K et al 
PLoS One. 2018 Apr 23;13(4):e0196239
 Paper

Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.
 Bhatt NB, Baudin E, Meggi B, da Silva C,  et al J
 Antimicrob Chemother. 2014 Sep 18.
Abstract


 FULL-TEXT ARTICLE
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial.
Turkova A, Moore CL, Butler K et al 
PLoS One. 2018 Apr 23;13(4):e0196239
 Paper

Pharmacokinetics of Rifampicin and Isoniazid in Tuberculosis-HIV Co-infected Patients Receiving Nevirapine or Efavirenz Based Antiretroviral Treatment (ANRS 12214 study).
 Bhatt NB, Barau C, Amin A, et al
Antimicrob Agents Chemother. 2014 Mar 24
 Abstract

FULL-TEXT ARTICLE
 Plasma Concentrations, Efficacy and Safety of Efavirenz in HIV-Infected Adults Treated for Tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA Trial).
 Borand L, Madec Y, Laureillard D, et al
PLoS One. 2014 Mar 7
 Paper

FULL-TEXT ARTICLE
 Therapeutic Drug Monitoring and Pharmacogenetic Study of HIV-Infected Ethnic Chinese Receiving Efavirenz-Containing Antiretroviral Therapy with or without Rifampicin-Based Anti-Tuberculous Therapy.
Lee KY, Lin SW, Sun HY,  et al
PLoS One. 2014 Feb 14;9(2):e88497.
Paper

FULL-TEXT  ARTICLE
 T Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive Individuals during Antituberculous Treatment and Efavirenz-Based Regimens.
 da Silva TP, Giacoia-Gripp CB, et al
PLoS One. 2013 Jun 19;8(6):e66095.
Paper

Impact of Pharmacogenetic Markers of CYP2B6, Clinical Factors, and Drug-Drug Interaction on Efavirenz Concentrations in HIV/Tuberculosis Co-Infected Patients.
Manosuthi W, Sukasem C, Lueangn
Abstract

FULL-TEXT ARTICLE
Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients.
Yimer G, Ueda N, Habtewold A, Amogne W,  et al
PLoS One. 2011;6(12):e27810
 Paper

The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.
 Gengiah TN, Holford NH, Botha JH, et al
Eur J Clin Pharmacol. 2011 Nov 23.
 Abstract

Efficacy and Safety of Once-Daily Nevirapine- or Efavirenz-Based Antiretroviral Therapy in HIV-Associated Tuberculosis: A Randomized Clinical Trial.
 Swaminathan S, Padmapriyadarsini C, Venkatesan P,  et al
Clin Infect Dis. 2011 Oct;53(7):716-24.
 Abstract

Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?
 Orrell C, Cohen K, Conradie F, et al
Antivir Ther. 2011;16(4):527-34.
 Abstract

Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy.
 Kwara A, Lartey M, Sagoe KW, Court MH.
AIDS. 2010 Dec 9
 Abstract

Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults.
 Uttayamakul S, Likanonsakul S, Manosuthi W,  et al
 AIDS Res Ther. 2010 Mar 26;7(1):8
 Abstract

Body Weight Cutoff for Daily Dosage of Efavirenz and 60-week Efficacy of Efavirenz-based Regimen in Co-infected HIV and Tuberculosis Patients Receiving Rifampin.
Manosuthi W, Sungkanuparph S, Tantanathip P,  et al
Antimicrob Agents Chemother. 2009 Aug 10
 Abstract

Pharmacokinetics of Efavirenz When Co-administered With Rifampin in TB/HIV Co-infected Patients: Pharmacogenetic Effect of CYP2B6 Variation.
 Kwara A, Lartey M, Sagoe KW, et al  
J Clin Pharmacol. 2008 Sep;48(9):1032-40.
 Abstract
 
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
 Friedland G, Khoo S, Jack C, Lalloo U.  
J Antimicrob Chemother. 2006 Oct 10;
Abstract

Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, et al
J Antimicrob Chemother. 2006 Sep 6;
 Abstract
HIV/Malaria Coinfection
 
  The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
 Maganda BA, Ngaimisi E, Kamuhabwa AA,  et al
Malar J. 2015 Apr 25;14(1):179.
 Abstract

Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.
 Huang L, Parikh S, Rosenthal PJ,  et al
J Acquir Immune Defic Syndr 2012 Aug 22
 Abstract

Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.
 van Luin M, Van der Ende ME, Richter C,  et al 
AIDS. 2010 May 15;24(8):1223-6.
 Abstract
HBV infection
 
  The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir.
 Qin B, Budeus B, Cao L, et al
Antiviral Res. 2012 Dec 19
 Abstract
TB infection
 
  Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment.
 Gengiah TN, Botha JH, Yende-Zuma N, et al
Antivir Ther. 2014 Oct 15
 Abstract
Oncology
 
  First results of a phase II trial to assess the efficacy of efavirenz in patients with metastatic androgen-independent prostate cancer.
 Houede N, Pulido M, Mourey L, et al
J Clin Oncol. 2012 Feb 10;30(5_suppl):251.
 Abstract

FULL-TEXT ARTICLE
Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells
 Hecht M, Erber S, Harrer T, et al
PLoS One. 2015 Jun 18;10(6):e0130277.
 Paper

A Phase II Trial Evaluating the Efficacy and Safety of Efavirenz in Metastatic Castration-Resistant Prostate Cancer.
 Houédé N, Pulido M, Mourey L,  et al
Oncologist. 2014 Oct 29.
Abstract

Efavirenz Adult Treatment Main New/Newsworthy  Home Page      

Efavirenz Journal Citations: Adult/Adolescent Treatment